Trial Profile

A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bezuclastinib (Primary) ; Sunitinib (Primary)
Indications Gastrointestinal stromal tumours
Focus Pharmacokinetics; Registrational; Therapeutic Use
Acronyms PEAK
Sponsors Cogent Biosciences

Most Recent Events

10 Nov 2025 According to a Cogent Biosciences media release, the company plans to present detailed results from the PEAK trial at an upcoming scientific conference in the first half of 2026.
10 Nov 2025 Results presented in the Cogent Biosciences media release.
20 Oct 2025 According to a Cogent Biosciences Media Release, company will announce top-line results from PEAK in November 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com